小青龙汤加味在支气管哮喘患者的临床效果及安全性研究

Study on the Clinical Efficacy and Safety of Xiaoqinglong Tonga in Patients with Bronchial Asthma

目的探讨小青龙汤加味在支气管哮喘患者中的临床效果及安全性。方法选择2017年4月—2018年1月入院治疗的支气管哮喘患者90例,根据治疗方法分为对照组(n=45例)和观察组(n=45例)。对照组采用常规方法治疗,观察组采用小青龙汤加味治疗,两组均进行1个月治疗,治疗完毕后对患者效果进行评估,比较两组临床疗效及安全性。结果观察组治疗后1个月FEV1、FEV1/FVC水平,均高于对照组(P<0.05);观察组治疗后1个月PEF水平,低于对照组(P<0.05);观察组治疗后1个月恶心呕吐、腹泻、皮疹、血压升高及过敏发生率为6.67%,低于对照组15.56%(P<0.05)。结论将小青龙汤加味用于支气管哮喘患者中有助于改善患者肺功能水平,安全性较高,值得推广应用。

Objective To investigate the clinical efficacy and safety of Xiao Qinglong Decoction in patients with bronchial asthma. Methods 90 cases of bronchial asthma who were hospitalized in January-2018 April 2017 were selected and divided into control group(n=45) and observation group(n=45 cases) according to the treatment Methods. The control group was treated with conventional Methods, and the observation group was treated with little Qinglong Decoction, and the two groups were treated for 1 months. After the treatment, the effect of the patients was evaluated, and the clinical efficacy and safety of the two groups were compared. Results The level of FEV1 and FEV1/FVC at 1 months after treatment in the observation group was higher than that of the control group(P<0.05), and the level of PEF in the observation group was lower than that of the control group(P<0.05) for 1 months after treatment, and the incidence of nausea and vomiting, diarrhea, rash, blood pressure and allergy in the observation group was 6.67% after 1 months of treatment, which was lower than that of the control group 15.56%(P<0.05). Conclusion Modified qingqinglong decoction can improve the lung function of patients with bronchial asthma. It is safe and worthy of popularization and application.